Published in Clin Cancer Res on March 24, 2009
The power of protein interaction networks for associating genes with diseases. Bioinformatics (2010) 1.96
Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci U S A (2009) 1.54
Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol (2009) 1.30
Melanoma in adolescents and young adults (ages 15-39 years): United States, 1999-2006. J Am Acad Dermatol (2011) 1.20
B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol (2010) 1.10
Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. Mol Carcinog (2011) 1.07
An integrative view on sex differences in brain tumors. Cell Mol Life Sci (2015) 1.04
Germline mutations and polymorphisms in the origins of cancers in women. J Oncol (2010) 0.96
Cell cycle gene networks are associated with melanoma prognosis. PLoS One (2012) 0.88
Zebrafish have a competent p53-dependent nucleotide excision repair pathway to resolve ultraviolet B-induced DNA damage in the skin. Zebrafish (2009) 0.86
Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer. Oncogene (2014) 0.78
The relationship between MDM2 expression and tumor thickness and invasion in primary cutaneous malignant melanoma. J Res Med Sci (2012) 0.77
MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer. Sci Rep (2016) 0.75
Intratumoral and Peritumoral Mast Cells in Malignant Melanoma: An Immunohistochemical Study. Adv Biomed Res (2017) 0.75
MDM2 gene polymorphisms and risk of classic Kaposi's sarcoma among Iranian patients. Med Microbiol Immunol (2017) 0.75
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
Regulation of p53 stability by Mdm2. Nature (1997) 18.20
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett (1996) 4.77
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res (2006) 3.26
MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets (2005) 3.04
Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol (1995) 2.30
Menopause. Lancet (2008) 2.15
Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem (2000) 2.00
Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst (2006) 1.88
Malignant melanoma and oral contraceptive use among women in California. Br J Cancer (1977) 1.76
A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res (2007) 1.67
The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res (2005) 1.56
p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol (2003) 1.54
Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst (2006) 1.51
Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer (2006) 1.51
Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat (2006) 1.49
Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res (1999) 1.41
Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res (2008) 1.37
MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol (2006) 1.37
Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res (1999) 1.37
MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet (2006) 1.35
The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet (2005) 1.34
Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res (2007) 1.29
Haplotype structure and selection of the MDM2 oncogene in humans. Proc Natl Acad Sci U S A (2007) 1.28
Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst (1983) 1.27
MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res (2007) 1.25
Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res (2004) 1.25
Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res (2004) 1.18
MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat (2007) 1.16
Effect of pregnancy on survival in women with cutaneous malignant melanoma. J Clin Oncol (2004) 1.08
Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol (2006) 1.07
The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in US Caucasian women. Mol Carcinog (2006) 1.07
MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer (1997) 1.07
Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol (1999) 1.07
Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol (2006) 1.04
HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst (2002) 0.98
Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer (2006) 0.98
p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants. Br J Dermatol (2007) 0.98
Influence of estrogen administration on tumor characteristics and survival in women with cutaneous melanoma. J Natl Cancer Inst (1985) 0.97
The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer (1988) 0.96
No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. Br J Dermatol (2007) 0.95
Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. Int J Cancer (2006) 0.95
Malignant melanoma and pregnancy. Melanoma Res (2006) 0.95
Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J Invest Dermatol (1995) 0.94
MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer (2007) 0.94
AKT regulation of estrogen receptor beta transcriptional activity in breast cancer. Cancer Res (2006) 0.93
Reproductive risk factors for cutaneous melanoma in women: a case-control study. Am J Epidemiol (2006) 0.93
Increased nevus estrogen and progesterone ligand binding related to oral contraceptives or pregnancy. J Am Acad Dermatol (1986) 0.89
Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. J Med Genet (2006) 0.89
A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Cancer Causes Control (2008) 0.88
Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer (1999) 0.88
Thickness of malignant melanoma: global analysis of related factors. J Dermatol Surg Oncol (1987) 0.88
The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation. Ann Surg Oncol (2002) 0.87
Use of tamoxifen in the treatment of malignant melanoma. Cancer (2003) 0.86
Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol Biomarkers Prev (1994) 0.85
Estrogen and progesterone receptor analysis in pregnancy-associated melanoma: absence of immunohistochemically detectable hormone receptors. Hum Pathol (1994) 0.84
An information-theoretic analysis of genetics, gender and age in cancer patients. PLoS One (2008) 0.83
The influence of hormones on melanogenesis. Australas J Dermatol (1969) 0.82
MDM2/p53 protein expression in the development of colorectal adenocarcinoma. J Gastrointest Surg (2000) 0.82
Absence of estrogen receptors in dysplastic nevi and malignant melanoma. J Am Acad Dermatol (1990) 0.81
Estrogen receptor status in malignant melanoma. Am J Dermatopathol (1990) 0.80
Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody. Arch Dermatol (1987) 0.78
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A (2009) 4.00
Colloquium paper: genome-wide patterns of population structure and admixture among Hispanic/Latino populations. Proc Natl Acad Sci U S A (2010) 3.20
Dominant and recessive deafness caused by mutations of a novel gene, TMC1, required for cochlear hair-cell function. Nat Genet (2002) 3.10
The history of African gene flow into Southern Europeans, Levantines, and Jews. PLoS Genet (2011) 2.81
Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res (2003) 2.62
Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA (2004) 2.58
Abraham's children in the genome era: major Jewish diaspora populations comprise distinct genetic clusters with shared Middle Eastern Ancestry. Am J Hum Genet (2010) 2.54
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature (2010) 2.49
ABCDE--an evolving concept in the early detection of melanoma. Arch Dermatol (2005) 2.47
Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One (2012) 2.40
Prone vs supine positioning for breast cancer radiotherapy. JAMA (2012) 2.32
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A (2009) 2.32
miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell (2011) 2.30
Survival after surgery in stage IA and IB non-small cell lung cancer. Am J Respir Crit Care Med (2007) 2.24
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A (2007) 2.19
Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol (2005) 2.18
Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol (2012) 2.02
Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol (2009) 1.99
Survival in familial dysautonomia: Impact of early intervention. J Pediatr (2002) 1.98
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 1.94
International experience, electives, and volunteerism in surgical training: a survey of resident interest. J Am Coll Surg (2007) 1.91
DREAM4: Combining genetic and dynamic information to identify biological networks and dynamical models. PLoS One (2010) 1.89
A versatile statistical analysis algorithm to detect genome copy number variation. Proc Natl Acad Sci U S A (2004) 1.88
Contrasting patterns of Y chromosome variation in Ashkenazi Jewish and host non-Jewish European populations. Hum Genet (2004) 1.85
Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst (2008) 1.78
Gene flow from North Africa contributes to differential human genetic diversity in southern Europe. Proc Natl Acad Sci U S A (2013) 1.77
Dexmedetomidine for awake carotid endarterectomy: efficacy, hemodynamic profile, and side effects. J Neurosurg Anesthesiol (2004) 1.73
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.69
High cost of stage IV pressure ulcers. Am J Surg (2010) 1.68
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68
microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J (2011) 1.66
IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol (2013) 1.65
TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.64
Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res (2010) 1.59
Facial follicular porokeratosis: a case report. Am J Dermatopathol (2010) 1.58
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology (2002) 1.57
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
On the etiology of contact/occupational vitiligo. Pigment Cell Res (2004) 1.55
Fludrocortisone in patients with familial dysautonomia--assessing effect on clinical parameters and gene expression. Clin Auton Res (2005) 1.52
A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. PLoS Genet (2012) 1.52
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
Prone accelerated partial breast irradiation after breast-conserving surgery: preliminary clinical results and dose-volume histogram analysis. Int J Radiat Oncol Biol Phys (2004) 1.51
Is surgical excision necessary for the management of atypical lobular hyperplasia and lobular carcinoma in situ diagnosed on core needle biopsy?: a report of 38 cases and review of the literature. Arch Pathol Lab Med (2008) 1.49
Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. Cancer Immun (2007) 1.46
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res (2012) 1.46
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res (2013) 1.43
Focus on melanoma. Cancer Cell (2002) 1.43
Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer (2003) 1.42
Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.39
Necrobiotic xanthogranuloma. Dermatol Online J (2012) 1.39
Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med (2004) 1.38
A mutation of PCDH15 among Ashkenazi Jews with the type 1 Usher syndrome. N Engl J Med (2003) 1.38
Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype. J Clin Invest (2011) 1.37
PCAdmix: principal components-based assignment of ancestry along each chromosome in individuals with admixed ancestry from two or more populations. Hum Biol (2012) 1.37
Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer (2010) 1.31
Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol (2006) 1.29
Pink-eyed dilution protein controls the processing of tyrosinase. Mol Biol Cell (2002) 1.29
Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res (2005) 1.29
The diagnostic performance of expert dermoscopists vs a computer-vision system on small-diameter melanomas. Arch Dermatol (2008) 1.28
Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res (2008) 1.28
Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res (2014) 1.27
Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med (2002) 1.26
Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. FASEB J (2010) 1.23
Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol (2007) 1.23
Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol Med (2013) 1.23
Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell (2011) 1.22
Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate a common signal transduction pathway in human testis determination. Am J Hum Genet (2010) 1.21
Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol (2009) 1.21